Adalimumab (anti-TNF-α) is a human monoclonal IgG1 antibody targeting tumour necrosis factor?α (TNF-α).
性状
Liquid
体外研究(In Vitro)
Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab (anti-TNF-α) than used in this study. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
The elimination half-life (t 1/2 ) of Adalimumab (anti-TNF-α) is long (~20 days). The enriched fluorescent-labelled adalimumab (anti-TNF-α) is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr mice. has not independently confirmed the accuracy of these methods. They are for reference only.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献
[1]. Ternant D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015 Feb;79(2):286-97.[2]. Oberoi R, et al. Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS One. 2016 Jul 28;11(7):e0160145.